ADC Therapeutics (ADCT) Accumulated Expenses (2019 - 2026)

ADC Therapeutics (ADCT) has reported Accumulated Expenses for 8 consecutive years, with $57.7 million the latest figure, recorded in Q1 2026.

• Quarterly Accumulated Expenses rose 36.72% year-over-year to $57.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.7 million (up 36.72% YoY) and the FY2025 annual result came in at $58.0 million, down 7.13% from the prior year.
• Accumulated Expenses fell to $57.7 million in Q1 2026 per ADCT's latest filing, from $58.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for ADCT reached as high as $68.5 million in Q4 2022 and fell as low as $40.4 million in Q1 2022.
• A 5-year average of $54.0 million and a median of $53.5 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 77.87% — and 2023, when it declined 23.93%.
• Year by year, Accumulated Expenses stood at $68.5 million in 2022, then dropped by 23.93% to $52.1 million in 2023, then rose by 19.84% to $62.4 million in 2024, then fell by 7.13% to $58.0 million in 2025, then retreated by 0.5% to $57.7 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $57.7 million, $58.0 million, and $53.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.